Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Latimer

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 1, 2023
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology AssessmentAsh Bullement, Matthew D Stevenson, Gianluca Baio, et al.
Targeted Oncology|December 17, 2016
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate CancerKonstantina Skaltsa, Cristina Ivanescu, Shevani Naidoo, et al.
Cancer Medicine|May 13, 2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapyNicholas R Latimer, Helen Bell, Keith R Abrams, et al.
Journal of the American Veterinary Medical Association|December 1, 2017
Lung lobe torsion in seven juvenile dogsChristian R Latimer, Cassie N Lux, Jessie S Sutton, et al.
Pharmacoeconomics|July 26, 2014
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalNicholas R Latimer, Christopher Carroll, Ruth Wong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 20, 2023
Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause SurvivalSangyu Lee, Paul C Lambert, Michael J Sweeting, et al.
The Oncologist|June 5, 2015
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus DacarbazineNicholas R Latimer, Keith R Abrams, Mayur M Amonkar, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 28, 2023
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates MattersAngus C Jennings, Mark J Rutherford, Nicholas R Latimer, et al.
Statistical Methods in Medical Research|April 27, 2016
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation studyNicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension StudyHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 1, 2023
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology AssessmentAsh Bullement, Matthew D Stevenson, Gianluca Baio, et al.
Targeted Oncology|December 17, 2016
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate CancerKonstantina Skaltsa, Cristina Ivanescu, Shevani Naidoo, et al.
Cancer Medicine|May 13, 2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapyNicholas R Latimer, Helen Bell, Keith R Abrams, et al.
Journal of the American Veterinary Medical Association|December 1, 2017
Lung lobe torsion in seven juvenile dogsChristian R Latimer, Cassie N Lux, Jessie S Sutton, et al.
Pharmacoeconomics|July 26, 2014
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalNicholas R Latimer, Christopher Carroll, Ruth Wong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 20, 2023
Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause SurvivalSangyu Lee, Paul C Lambert, Michael J Sweeting, et al.
The Oncologist|June 5, 2015
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus DacarbazineNicholas R Latimer, Keith R Abrams, Mayur M Amonkar, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 28, 2023
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates MattersAngus C Jennings, Mark J Rutherford, Nicholas R Latimer, et al.
Statistical Methods in Medical Research|April 27, 2016
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation studyNicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension StudyHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Pageof 9